Challenging the dogma: a randomized trial of standard vs. half-dose concomitant nonbismuth quadruple therapy for Helicobacter pylori infection.

ABSTRACT:

Background

Current treatment of Helicobacter pylori consists of three or four drugs for 7-14 days with important associated cost and adverse events.

Aims

This study compared efficacy and safety of standard dose vs. half-dose concomitant nonbismuth quadruple therapy (NBQT) for 7 days. The standard dose consisted of twice daily rabeprazole 20 mg, amoxicillin 1 g, metronidazole 500 mg, and clarithromycin 500 mg.

Methods

This was a prospective randomized trial. (14)C-urea breath test was performed ≥4 weeks after treatment and ≥2 weeks off acid suppressive therapy. Compliance and adverse events were monitored during treatment.

Results

A total of 200 consecutive treatment-naïve patients were enrolled. Baseline characteristics were similar between groups, with 15.5% o

SUBMITTER: Sharara AI 

PROVIDER: S-EPMC4212457 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature